Get Updates

Sign up to get access to information on Doptelet and chronic ITP—related tips that aim to help your patients set and reach their treatment goals.

You can unsubscribe anytime!

Doptelet Platelet Character Hot Air Balloon

Fill out the form below

First Name

Last Name

Email address

Phone number

NPI

Address

+ Add second address line

Address 2

City

State or Territory

ZIP code

I certify that I am a US healthcare professional.

I understand that any information I provide through this website is in accordance with the Sobi Terms and Conditions and Privacy Policy.

I agree to enroll in promotional email communications for Doptelet.

Sobi may use my information for market research or to evaluate and improve the company’s services and programs. I understand that I may stop Sobi from contacting me at any time by clicking the “Unsubscribe” link in the emails I receive from Sobi. I understand that Sobi will not sell or rent my personally identifiable information.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET^® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

The most common serious adverse reaction reported in DOPTELET-treated patients compared to placebo was hyponatremia (0.7% v. 0%).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

Colorado prescribers, for WAC pricing, visit doptelethcp.com/wac-pricing.